SLC16A6: A Potential Drug Target and Biomarker for Cancer (G9120)

Target Name: SLC16A6

NCBI ID: G9120

SLC16A6

SLC16A6: A Potential Drug Target and Biomarker for Cancer

SLC16A6 (MCT7), a protein located on the surface of certain cancer cells, has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new treatments.

SLC16A6 is a member of the solute carrier family 16 (SLC16) and is responsible for transporting various molecules across cell membranes. This protein has been identified in various organisms, including humans, and has been shown to play a role in various physiological processes.

One of the most promising aspects of SLC16A6 is its potential as a drug target. The high degree of conservation between SLC16A6 and various drug targets, such as the HER2 protein, makes it an attractive candidate for targeting with small molecules. Additionally, its expression pattern has been shown to be regulated by various signaling pathways, which may make it more responsive to certain types of treatments.

SLC16A6 has also been shown to be a potential biomarker for various diseases, including cancer. Its expression has been associated with the development and progression of various cancers, including breast, ovarian, and prostate cancers. Additionally, its expression has been shown to be downregulated in various cancer-associated tissues, which may make it a potential diagnostic biomarker for these diseases.

The discovery and characterization of SLC16A6 as a potential drug target and biomarker has the potential to lead to new and more effective treatments for a variety of diseases. Further research is needed to fully understand its role and potential as a drug target and biomarker, and to develop new treatments based on this protein.

In conclusion, SLC16A6 is a protein with great potential as a drug target and biomarker for the treatment of various diseases. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand its role and potential in the treatment of cancer and other diseases.

Protein Name: Solute Carrier Family 16 Member 6

Functions: Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity)

The "SLC16A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets